These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32879206)

  • 1. Effect of Chronic Kidney Disease on Hepatic Clearance of Drugs in Rats.
    Tokunaga A; Miyamoto H; Fumoto S; Nishida K
    Biol Pharm Bull; 2020; 43(9):1324-1330. PubMed ID: 32879206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased elimination clearance of midazolam by doxorubicin through reductions in the metabolic activity of hepatic CYP3A in rats.
    Nagai K; Yoshida N; Kiyama M; Kasahara K; Yamamura A; Konishi H
    Xenobiotica; 2015; 45(10):874-80. PubMed ID: 26053556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conflicting alterations in hepatic expression of CYP3A and enzyme kinetics in rats exposed to 5-fluorouracil: relevance to pharmacokinetics of midazolam.
    Fukuno S; Nagai K; Fujiike M; Sasaki Y; Konishi H
    Xenobiotica; 2019 Dec; 49(12):1470-1477. PubMed ID: 30714842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Assessment of the Effect of Chronic Kidney Disease on the Nonrenal Clearance of 10 Drugs After Intravenous Administration.
    Hinderling PH; Yu Y
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):138-151. PubMed ID: 30589517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of renal ischaemia/reperfusion-induced acute kidney injury on pharmacokinetics of midazolam in rats.
    Tokunaga A; Miyamoto H; Fumoto S; Nishida K
    J Pharm Pharmacol; 2019 Dec; 71(12):1792-1799. PubMed ID: 31579949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.
    Thomson BK; Nolin TD; Velenosi TJ; Feere DA; Knauer MJ; Asher LJ; House AA; Urquhart BL
    Am J Kidney Dis; 2015 Apr; 65(4):574-82. PubMed ID: 25453994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in pharmacokinetic behavior of intravenously administered midazolam due to increased CYP3A2 expression in rats treated with menthol.
    Nagai K; Suzuki S; Yamamura A; Konishi H
    Biopharm Drug Dispos; 2015 Apr; 36(3):174-82. PubMed ID: 25430017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.
    Sayama H; Takubo H; Komura H; Kogayu M; Iwaki M
    AAPS J; 2014 Sep; 16(5):1018-28. PubMed ID: 24912798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in vivo effects of adenine-induced chronic kidney disease on some renal and hepatic function and CYP450 metabolizing enzymes.
    Al Za'abi M; Shalaby A; Manoj P; Ali BH
    Physiol Res; 2017 May; 66(2):263-271. PubMed ID: 27982683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of chronic kidney disease on CYP2B expression and activity in male Wistar rats.
    Kucey AS; Velenosi TJ; Tonial NC; Tieu A; RaoPeters AAE; Urquhart BL
    Pharmacol Res Perspect; 2019 Jun; 7(3):e00475. PubMed ID: 31049204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of indocyanine green in rats with experimentally induced hepatic diseases.
    Kimura T; Nakayama S; Yamao T; Kurosaki Y; Nakayama T
    Biol Pharm Bull; 1993 Nov; 16(11):1140-5. PubMed ID: 8312872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic synthesis and urinary elimination of acetaminophen glucuronide are exacerbated in bile duct-ligated rats.
    Villanueva SS; Ruiz ML; Ghanem CI; Luquita MG; Catania VA; Mottino AD
    Drug Metab Dispos; 2008 Mar; 36(3):475-80. PubMed ID: 18096675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nutritional Status Differentially Alters Cytochrome P450 3A4 (CYP3A4) and Uridine 5'-Diphospho-Glucuronosyltransferase (UGT) Mediated Drug Metabolism: Effect of Short-Term Fasting and High Fat Diet on Midazolam Metabolism.
    Lammers LA; Achterbergh R; Romijn JA; Mathôt RAA
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):751-767. PubMed ID: 29876844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A limited sampling strategy of phenotyping probe midazolam to predict inhibited activities of hepatic CYP3A in rats].
    Zhu XH; Jiao JJ; Zhang CL; Lou JS; Liu CX
    Yao Xue Xue Bao; 2008 Sep; 43(9):905-11. PubMed ID: 19048780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats.
    Bittner B; González RC; Isel H; Flament C
    Eur J Pharm Biopharm; 2003 Jul; 56(1):143-6. PubMed ID: 12837492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatobiliary excretion of acetaminophen glutathione conjugate and its derivatives in transport-deficient (TR-) hyperbilirubinemic rats.
    Chen C; Hennig GE; Manautou JE
    Drug Metab Dispos; 2003 Jun; 31(6):798-804. PubMed ID: 12756215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of carrageenan-induced acute peripheral inflammation on the pharmacokinetics and hepatic metabolism of midazolam in rats.
    Kajikawa N; Doi M; Kusaba J; Aiba T
    Drug Metab Pharmacokinet; 2014; 29(5):400-6. PubMed ID: 24717840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice.
    Kulkarni SG; Pegram AA; Smith PC
    AAPS PharmSci; 2000; 2(2):E18. PubMed ID: 11741234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro-in vivo extrapolation of bexarotene metabolism in the presence of chronic kidney disease and acute kidney injury in rat using physiologically based pharmacokinetic modeling and extrapolation to human.
    Alsmadi MM; Alzughoul SB
    Biopharm Drug Dispos; 2023 Jun; 44(3):221-244. PubMed ID: 36319070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subclinical chronic kidney disease modifies the diagnosis of experimental acute kidney injury.
    Succar L; Pianta TJ; Davidson T; Pickering JW; Endre ZH
    Kidney Int; 2017 Sep; 92(3):680-692. PubMed ID: 28476556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.